Lymphomas consists of a diverse group of malignant neoplasms. They derived from B cell progenitors, T cell progenitors, mature B cells, mature T cells, or natural killer cells. The World Health Organization (WHO) classifies tumors of the hematopoietic and lymphoid tissues according to their morphologic, immunophenotypic, genetic, and clinical features and this classification was revised in 2016. The pathogenesis of lymphomas still continues to dissolve and new biological subtypes are identified, and new information is added. These developments and changes bring new suggestions for the diagnostic, prognostic evaluation and treatment of lymphomas. A large number of new agents were introduced for the the treatment of lymphomas in the last 20 years. New monoclonal antibodies and targeted agents acting on each of its specific mechanisms have been successfully applied to different lymphoma subtypes. In addition, phase studies of many agents are still ongoing, and the introduction of a significant number of patients into these studies is a necessity in today's lymphoma treatment practice.

Aims and Scope:

1. Lymphoma
2. Chemotherapy
3. Antibodies
4. Biology
5. Small molecules
6. Molecular pathogenesis